SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011

• Published in: International journal of gynecology and obstetrics 2011-08, Vol.114 (2), p.190-202
• Main Authors: Wong, Suzanne, Ordean, Alice, Kahan, Meldon
• Format: Article
• Language: English
• Subjects: Canada; Female; Health Services Accessibility; Humans; Infant Mortality; Infant, Newborn; Maternal Health Services - economics; Maternal Mortality; Pregnancy; Pregnancy Complications - diagnosis; Pregnancy Complications - therapy; Randomized Controlled Trials as Topic; Substance-Related Disorders - diagnosis; Substance-Related Disorders - therapy
• ISSN: 1879-3479

To improve awareness and knowledge of problematic substance use in pregnancy and to provide evidence-based recommendations for the management of this challenging clinical issue for all health care providers. This guideline reviews the use of screening tools, general approach to care, and recommendations for clinical management of problematic substance use in pregnancy. Evidence-based recommendations for screening and management of problematic substance use during pregnancy and lactation. Medline, PubMed, CINAHL, and The Cochrane Library were searched for articles published from 1950 using the following key words: substance-related disorders, mass screening, pregnancy complications, pregnancy, prenatal care, cocaine, cannabis, methadone, opioid, tobacco, nicotine, solvents, hallucinogens, and amphetamines. Results were initially restricted to systematic reviews and randomized control trials/controlled clinical trials. A subsequent search for observational studies was also conducted because there are few RCTs in this field of study. Articles were restricted to human studies published in English. Additional articles were located by hand searching through article reference lists. Searches were updated on a regular basis and incorporated in the guideline up to December 2009. Grey (unpublished) literature was also identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on the Preventive Health Care. Recommendations for practice were ranked according to the method described in that report (Table 1). This guideline is intended to increase the knowledge and comfort level of health care providers caring for pregnant women who have substance use disorders. Improved access to health care and assistance with appropriate addiction care leads to reduced health care costs and decreased maternal and neonatal morbidity and mortality.